New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Expanding US operations to address the increased demand for API development and manufacturing
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Takeda will seek an external partner to leverage its cell therapy platform technologies
IND application for EB-003 expected in early 2026
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Subscribe To Our Newsletter & Stay Updated
